Mu Nie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mu Nie has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Anthony Wong
Karolinska Institutet
1 shared publicationDan-Dan Yang
Department of Hematology, Qilu Hospital, Shandong University, Jinan, China
1 shared publication- Emma Hendriks
Karolinska Institutet
1 shared publication - Feng Qi
Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
1 shared publication - Gunnar Nilsson
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet, and Clinical Immunology and Transfusion Medicine Karolinska University Hospital, Solna, and Center for Molecular Medicine, Karolinska University Hospital Solna Sweden
1 shared publication - Guosheng Li
Energy and Environment Directorate Pacific Northwest National Laboratory Richland Washington USA
1 shared publication
Latest Publications
- 1 May 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (5) , L638-L649
Allergic airway inflammation amplifies mast cell responses in isolated guinea pig intralobular bronchi
A protocol to avoid postmortem constriction in isolated intralobular bronchi from guinea pigs was established. A new model makes it possible to investigate bronchial responses in airways with asthmatic features. Increased responses in bronchi from the guinea pig asthma model suggest the importance of mast cells in asthma.
- 1 May 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 328 (5) , L638-L649
Allergic airway inflammation amplifies mast cell responses in isolated guinea pig intralobular bronchi
A protocol to avoid postmortem constriction in isolated intralobular bronchi from guinea pigs was established. A new model makes it possible to investigate bronchial responses in airways with asthmatic features. Increased responses in bronchi from the guinea pig asthma model suggest the importance of mast cells in asthma.
- 26 February 2019
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 119 (05) , 758-765
PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis
The binding of programmed death 1 (PD-1) to its ligands PD-L1 and PD-L2 on antigen-presenting cells turns off autoreactive T cells and induces peripheral tolerance. Aberrant PD-1/PD-L signalling could result in a breakdown of peripheral tolerance and lead to autoimmune diseases. In this study, we detected PD-1 and PD-L expression on T cells and dendritic cells (DCs) in immune thrombocytopaenia (ITP) patients with active disease by flow cytometry. The effects of PD-L1-Fc fusion protein (PD-L1-Fc) on T cells and on secretion of interferon-γ (IFN-γ) and interleukin-2 (IL-2) were detected by flow cytometry and enzyme-linked immunosorbent assay, respectively. Compared with healthy controls, PD-1 expression was significantly increased in CD4+ T cells and CD8+ T cells from patients with active ITP. However, PD-L1 expression on monocyte-derived DCs was lower in patients with active ITP than in healthy controls. In vitro assays revealed that PD-L1-Fc increased T cell apoptosis, inhibited activation and proliferation of CD4+ T cells and CD8+ T cells and decreased IFN-γ and IL-2 secretion in patients with active ITP. These results suggest that the aberrant PD-1/PD-L negative co-stimulatory pathway may play a role in ITP. Enhancing PD-1/PD-L signalling might be a promising therapeutic approach for ITP patients by enhancing T cell apoptosis, inhibiting T cell activation and proliferation and reducing secretion of inflammatory factors. M.N. and X.-x.L. performed research, analysed data and wrote the manuscript; Y.L., D.-d.Y., Q.L. and Y.H. performed research; Y.-n.M. and Q.F. performed research and analysed data; G.-s.L. and J.-z.S. analysed data; Y.S. contributed vital new reagents, designed the study and wrote the manuscript; M.H. revised the manuscript; and all authors read and edited the manuscript. Part of this study was orally presented at the 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis, Taipei, Taiwan, China, October 6–9, 2016, and part of this study was presented as a poster at the 60th American Society of Hematology Annual Meeting, San Diego, California, United States, December 1–4, 2018. * M.N. and Y.L. contributed equally to this study.
- 26 February 2019
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 119 (05) , 758-765
PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis
The binding of programmed death 1 (PD-1) to its ligands PD-L1 and PD-L2 on antigen-presenting cells turns off autoreactive T cells and induces peripheral tolerance. Aberrant PD-1/PD-L signalling could result in a breakdown of peripheral tolerance and lead to autoimmune diseases. In this study, we detected PD-1 and PD-L expression on T cells and dendritic cells (DCs) in immune thrombocytopaenia (ITP) patients with active disease by flow cytometry. The effects of PD-L1-Fc fusion protein (PD-L1-Fc) on T cells and on secretion of interferon-γ (IFN-γ) and interleukin-2 (IL-2) were detected by flow cytometry and enzyme-linked immunosorbent assay, respectively. Compared with healthy controls, PD-1 expression was significantly increased in CD4+ T cells and CD8+ T cells from patients with active ITP. However, PD-L1 expression on monocyte-derived DCs was lower in patients with active ITP than in healthy controls. In vitro assays revealed that PD-L1-Fc increased T cell apoptosis, inhibited activation and proliferation of CD4+ T cells and CD8+ T cells and decreased IFN-γ and IL-2 secretion in patients with active ITP. These results suggest that the aberrant PD-1/PD-L negative co-stimulatory pathway may play a role in ITP. Enhancing PD-1/PD-L signalling might be a promising therapeutic approach for ITP patients by enhancing T cell apoptosis, inhibiting T cell activation and proliferation and reducing secretion of inflammatory factors. M.N. and X.-x.L. performed research, analysed data and wrote the manuscript; Y.L., D.-d.Y., Q.L. and Y.H. performed research; Y.-n.M. and Q.F. performed research and analysed data; G.-s.L. and J.-z.S. analysed data; Y.S. contributed vital new reagents, designed the study and wrote the manuscript; M.H. revised the manuscript; and all authors read and edited the manuscript. Part of this study was orally presented at the 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis, Taipei, Taiwan, China, October 6–9, 2016, and part of this study was presented as a poster at the 60th American Society of Hematology Annual Meeting, San Diego, California, United States, December 1–4, 2018. * M.N. and Y.L. contributed equally to this study.